Alpha Tau Medical (NASDAQ:DRTS) Shares Climb 5.2% – Still a Buy?

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) shares shot up 5.2% during trading on Friday. The stock traded as high as $11.82 and last traded at $11.90. 82,989 shares changed hands during trading, a decline of 86% from the average daily volume of 587,964 shares. The stock had previously closed at $11.31.

Wall Street Analyst Weigh In

DRTS has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Alpha Tau Medical in a research report on Tuesday. Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Monday, November 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Thursday, October 15th. Benchmark reissued a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Finally, UBS Group reiterated a “buy” rating on shares of Alpha Tau Medical in a research report on Tuesday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.20.

View Our Latest Stock Report on DRTS

Alpha Tau Medical Trading Up 2.7%

The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.05 billion, a P/E ratio of -11.17 and a beta of 1.28. The business’s 50-day moving average is $13.84 and its two-hundred day moving average is $11.01.

Institutional Investors Weigh In On Alpha Tau Medical

Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in shares of Alpha Tau Medical in the 1st quarter worth approximately $286,000. Principal Financial Group Inc. bought a new position in shares of Alpha Tau Medical in the first quarter valued at about $132,000. Finally, Everhart Financial Group Inc. bought a new stake in Alpha Tau Medical during the 2nd quarter worth about $126,000. 2.65% of the stock is owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

(Get Free Report)

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.

Featured Articles

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.